Mainz BiomedMYNZ
MYNZ
About: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Employees: 71
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
22% more funds holding
Funds holding: 9 [Q2] → 11 (+2) [Q3]
9% more capital invested
Capital invested by funds: $41.5K [Q2] → $45.3K (+$3.75K) [Q3]
0.36% more ownership
Funds ownership: 0.47% [Q2] → 0.83% (+0.36%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for MYNZ.
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the industry leading results of previous feasibility studies, which included average risk and identified risk patients.
Neutral
GlobeNewsWire
1 month ago
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Neutral
GlobeNewsWire
1 month ago
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Neutral
GlobeNewsWire
1 month ago
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Neutral
Benzinga
1 month ago
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.
Neutral
GlobeNewsWire
1 month ago
Mainz Biomed Announces Stock Split
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Neutral
GlobeNewsWire
3 months ago
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Neutral
GlobeNewsWire
3 months ago
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert
Neutral
GlobeNewsWire
3 months ago
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Neutral
GlobeNewsWire
4 months ago
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
BERKELEY, Calif. and MAINZ, Germany, Sept.
Charts implemented using Lightweight Charts™